

ASX ANNOUNCEMENT

CELLMID'S SHIPMENT OF SARS-CoV-2 TESTS RECEIVED

SYDNEY, Tuesday, 14 April 2020: Cellmid Limited (ASX: CDY) is pleased to advise that its first shipment of 12,000 SARS-CoV-2 rapid diagnostic tests has arrived in Sydney. The Wondfo Biotech manufactured SARS-CoV-2 point of care test (Wondfo POCT) detects antibodies to the SARS-CoV-2 (the virus causing COVID-19).

The presence of antibodies to SARS-CoV-2 confirms exposure and is likely to convey immunity to COVID-19. Cellmid expects the Wondfo POCT to be largely used to facilitate return to work programmes. The current shipment is intended to be sold to medical practitioners subject to the completion of internal testing. A limited number of tests will be held for external testing and research purposes.


Cellmid has received several hundred enquiries and expressions of interest to supply the Wondfo POCT to medical practititioners, hospitals and research groups. The Company is currently evaluating these requests and will be completing confirmatory testing in reparation for placing its second order with the manufacturer.

The Cellmid sponsored Wondfo SARS-CoV-2 kit is manufactured in a facility certified by the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA) under the Medical Device Single Audit Program (MDSAP) and is authorised to export its devices to Australia.

Authorised for release by the Board of Cellmid Limited.

Contact

Maria Halasz, CEO T +612 9221 6830



Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets. Cellmid's biotech asset portfolio includes diagnostics and therapeutics in relation to midkine, a novel disease target. In addition, the Company has recently secured a supply agreement for a SARS-CoV-2 point of care test. The Company's consumer health business develops and sell a range of antiaging hair care products. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.